###begin article-title 0
A Role for von Hippel-Lindau Protein in Pancreatic beta-Cell Function
###end article-title 0
###begin p 1
###xml 39 64 39 64 <email xmlns:xlink="http://www.w3.org/1999/xlink">mhebrok@diabetes.ucsf.edu</email>
Corresponding author: Matthias Hebrok, mhebrok@diabetes.ucsf.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 193 196 193 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 158 164 <span type="species:ncbi:9606">humans</span>
OBJECTIVE-The Vhlh gene codes for the von Hippel-Lindau protein (VHL), a tumor suppressor that is a key player in the cellular response to oxygen sensing. In humans, a germline mutation in the VHL gene leads to the von Hippel-Lindau disease, a familial syndrome characterized by benign and malignant tumors of the kidney, central nervous system, and pancreas.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre-lox</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 222 226 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 226 229 223 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
RESEARCH DESIGN AND METHODS-We use Cre-lox recombination to eliminate Vhlh in adult mouse pancreatic beta-cells. Morphology of mutant islets is assessed by immunofluorescence analysis. To determine the functional state of Vhlh-/- islets, insulin secretion is measured in vivo and in vitro, and quantitative PCR is used to identify changes in gene expression.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
RESULTS-Loss of VHL in beta-cells leads to a severe glucose-intolerant phenotype in adult animals. Although VHL is not required for beta-cell specification and development, it is critical for beta-cell function. Insulin production is normal in beta-cells lacking VHL; however, insulin secretion in the presence of high concentrations of glucose is impaired. Furthermore, the loss of VHL leads to dysregulation of glycolytic enzymes, pointing to a perturbation of the intracellular energy homeostasis.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 220 224 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
CONCLUSIONS-We show that loss of VHL in beta-cells leads to defects in glucose homeostasis, indicating an important and previously unappreciated role for VHL in beta-cell function. We believe that the beta-cell-specific Vhlh-deficient mice might be a useful tool as a "genetic hypoxia" model, to unravel the possible link between hypoxia signaling and impairment of beta-cell function.
###end p 6
###begin p 7
Published ahead of print at  on 25 November 2008.
###end p 7
###begin p 8
S.P. and D.C. contributed equally to this work.
###end p 8
###begin p 9
D.A.C. is currently affiliated with the Instituto de Biomedicina de Sevilla, Servicio de Endocrinologia y Nutricion, Hospitales Universitarios Virgen del Rocio, Sevilla, Spain.
###end p 9
###begin p 10
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 10
###begin p 11
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 688 689 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 690 691 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 850 851 842 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 852 853 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
Oxygen homeostasis is essential to cellular function, and low O2 pressure (hypoxia) has a profound impact on cell metabolism and physiological processes. The von Hippel-Lindau tumor suppressor protein (VHL) is a key player in the cellular response to oxygen sensing. Hypoxia inducible factors (HIFs) are global regulators of oxygen homeostasis, allowing cellular adaptation to oxygen deprivation by transcriptionally modulating genes involved in cellular energy metabolism, angiogenesis, apoptosis, and proliferation, among other biological processes (rev. in 1-5). During normoxia, prolyl hydroxylases hydroxylate specific residues on HIF-alpha, a modification that is oxygen dependent (6,7). VHL specifically recognizes these modified residues, targeting HIF-alpha for ubiquitination via E3 ubiquitin ligase and subsequent proteasomal degradation (8,9). Under hypoxic conditions, HIF-alpha is stabilized and forms a complex with the beta-subunit of a transcriptional complex (HIF-1beta, also called aryl hydrocarbon receptor nuclear translocator, or ARNT) that then translocates to the nucleus to modulate expression of downstream targets, including genes involved in oxygen uptake and glucose metabolism. In the absence of VHL, HIF-alpha-dependent genes are inappropriately upregulated in spite of normal oxygen levels.
###end p 11
###begin p 12
###xml 38 41 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 297 300 297 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 540 544 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 796 800 796 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 976 980 976 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1107 1109 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1110 1112 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
###xml 279 285 <span type="species:ncbi:10090">murine</span>
###xml 933 938 <span type="species:ncbi:9606">human</span>
###xml 939 947 <span type="species:ncbi:9606">patients</span>
In humans, a germline mutation in the VHL gene leads to the development of the von Hippel-Lindau disease, a rare familial syndrome characterized by benign and malignant tumors of several organs, including the kidney, central nervous system, and pancreas (10). In mice, Vhlh (the murine homolog of VHL) inactivation results in mid-gestation lethality (11). The use of conditional alleles has thus proven a powerful approach to investigate the role of this protein in specific organ development and function (12). Conditional inactivation of Vhlh has been successfully achieved in several organs including kidney, liver, and bone (13-15). These studies have demonstrated that VHL plays a fundamental role in survival, proliferation, and differentiation of many cell types. Specific inactivation of Vhlh in kidney cells results in the development of blood-filled cavities that are reminiscent of the hemangioblastomas typically seen in human patients (13). Specific depletion of Vhlh in the liver leads to steatosis within the liver, presumably due to alterations in the glycolytic machinery within the organ (14,16).
###end p 12
###begin p 13
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 224 231 221 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre-lox</italic>
###xml 269 273 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
Another hallmark of human VHL patients is the occurrence of cysts and tumors, including neuro-endocrine tumors, in the pancreas (17,18). To elucidate the role of VHL in pancreatic beta-cells, we have eliminated the gene via Cre-lox technology. Specific inactivation of Vhlh in beta-cells results in glucose intolerance in mice. This defect appears to be a consequence of a significant impairment in glucose-stimulated insulin secretion in beta-cells that lack VHL. Further analysis has revealed a profound change in the expression pattern of genes coding for glycolytic enzymes that regulate the metabolic state of the beta-cells. Thus, our data reveal a previously unappreciated role for VHL in maintaining a functional state in pancreatic beta-cells.
###end p 13
###begin title 14
RESEARCH DESIGN AND METHODS
###end title 14
###begin title 15
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
Transgenic mouse handling.
###end title 15
###begin p 16
###xml 183 190 183 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ins-Cre</italic>
###xml 195 204 195 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 204 206 204 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 204 206 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 318 327 318 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP/loxP</italic>
###xml 318 327 318 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>loxP/loxP</italic></sup>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
Mice used in these studies were maintained in the barrier facility according to protocols approved by the Committee on Animal Research at the University of California, San Francisco. Ins-Cre and Pdx-1-CreER (tamoxifen-inducible) mice were obtained from Drs. Pedro Herrera's and Doug Melton's laboratories, and the VhlhloxP/loxP mice have been described previously (14,19,20).
###end p 16
###begin p 17
###xml 12 15 12 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre</italic>
###xml 15 17 15 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 15 17 15 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 173 175 170 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 181 183 178 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 103 107 <span type="species:ncbi:381124">corn</span>
###xml 168 173 <span type="species:ncbi:10090">mouse</span>
To activate CreER in pancreatic beta-cells, tamoxifen (TAM; Sigma-Aldrich, St. Louis, MO) dissolved in corn oil (10 mg/ml) was administered intraperitoneally at 1 mg . mouse-1 . day-1 for 5 continual days.
###end p 17
###begin p 18
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
For DNA genotyping, islet DNA was collected in 1 ml AT-Extraction solution (0.067N ammonium hydroxide, 0.2% Triton X-100) and sonicated for 10 s in ice water. Genomic DNA was concentrated by ethanol precipitation and used for PCR as previously described (19-21).
###end p 18
###begin title 19
Histology and immunofluorescence analysis.
###end title 19
###begin p 20
###xml 549 551 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 961 963 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 598 608 <span type="species:ncbi:10141">guinea pig</span>
###xml 630 636 <span type="species:ncbi:9986">rabbit</span>
###xml 693 699 <span type="species:ncbi:9986">rabbit</span>
###xml 744 749 <span type="species:ncbi:10090">mouse</span>
###xml 821 827 <span type="species:ncbi:9986">rabbit</span>
###xml 878 881 <span type="species:ncbi:10116">rat</span>
###xml 932 938 <span type="species:ncbi:9986">rabbit</span>
For paraffin sections, isolated pancreata from adult mice were fixed in 4% (wt/vol) paraformaldehyde in PBS for 4 h to overnight at 4degreesC. For frozen sections, adult tissue was fixed in 4% (wt/vol) paraformaldehyde for 2 h at room temperature and incubated overnight in 30% (wt/vol) sucrose in PBS. The following day, tissues were frozen in optical cutting temperature cryoembedding media (OCT) after two washes in PBS and stored at -80degreesC. Hematoxylin/eosin staining and immunofluorescence analyses were performed as described previously (22). The following primary antibodies were used: guinea pig anti-insulin, 1:300; rabbit anti-glucagon, 1:300 (Linco Research, St. Charles, MO); rabbit anti-Glut2, 1:500 (Chemicon, Temecula, CA); mouse anti-Pax6, 1:25 (Developmental Studies Hybridoma Bank, Iowa City, IA); rabbit anti-somatostatin, 1:200 (Dako, Carpentaria, CA); rat anti-CD31, 1:100 (Pharmingen, San Diego, CA); and rabbit anti-Nkx6.1, 1:1,000 (23). Primary antibodies were detected with FITC-conjugated (1:200) and Cy3-conjugated (1:600) secondary antibodies (Jackson ImmunoResearch Laboratory, West Grove, PA).
###end p 20
###begin p 21
Bright field images were acquired using a Zeiss Axio Imager D1 microscope. Fluorescence was visualized and photographed with a Zeiss Axiphoto2 plus microscope. Unless otherwise noted, all photomicrographs shown are representative of at least three independent samples of the indicated genotype.
###end p 21
###begin title 22
Quantitative PCR.
###end title 22
###begin p 23
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
RNA isolation, cDNA preparation, and qPCR were performed as described previously (24). RNA expression of target genes was normalized based on comparison to cyclophilin expression. Primer sequences are available on request.
###end p 23
###begin title 24
Intraperitoneal glucose tolerance test and acute insulin secretory response in vivo.
###end title 24
###begin p 25
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 120 124 <span type="species:ncbi:10090">Mice</span>
After a 16- to 18-h fast, mice were weighed and fasting blood glucose level was measured using the Lifescan Glucometer. Mice were injected intraperitoneally with a 1 mol/l glucose solution at 10 mul per gram body weight. Blood glucose levels were then measured every 30 min for 2 h after injection. For in vivo insulin measurement, blood was collected from the tail vein before and 30 min after glucose injection. Serum containing protease inhibitors (Roche, Indianapolis, IN) was stored at -80degreesC. Insulin concentration was calculated using the Insulin EIA kit (ALPCO) as per the manufacturer's instructions.
###end p 25
###begin title 26
Islet isolation and in vitro insulin secretion.
###end title 26
###begin p 27
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 549 550 542 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
The Islet Production Facility Core at the Diabetes Center at University of California-San Francisco (UCSF) isolated islets from adult mice. Glucose-stimulated insulin secretion in isolated islets was performed as previously described (25). To quantify the secretory response in the presence of K+, 40 mmol/l KCl was added to the high glucose solution before incubation with the islets. For total insulin content of islets, insulin was extracted overnight at 4degreesC with acid/ethanol (1.5% HCl/75% ethanol) (300 mul). After centrifugation at 1,000g for 3 min, the supernatant was collected and frozen at -20degreesC for insulin determination as described above.
###end p 27
###begin title 28
Insulin tolerance test.
###end title 28
###begin p 29
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 76 80 <span type="species:ncbi:10090">Mice</span>
After a 16- to 18-h fast, mice were weighed and blood glucose was measured. Mice were injected intraperitoneally with a dose of 1 unit/kg of body weight. Blood glucose levels were measured every 30 min for 2 h after injection.
###end p 29
###begin title 30
Islet lactate secretion assay.
###end title 30
###begin p 31
###xml 32 41 32 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1&#8211;Cre</italic>
###xml 41 43 41 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 41 43 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 48 57 48 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 48 57 48 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
Islets isolated from control or Pdx-1-CreER;VhlhLoxP/LoxP animals were incubated overnight in 200 mul growth medium with 16.7 mmol/l glucose. After the incubation, 20 mul supernatant was used in duplicate to measure lactate using a Lactate Assay Kit (Eton Biosciences, San Diego, CA). The islets were processed for RNA isolation using the RNeasy Mini Kit (Qiagen Sciences, MD). The amount of lactate was normalized to total RNA.
###end p 31
###begin title 32
Islet area quantification.
###end title 32
###begin p 33
Paraffin-embedded tissue was sectioned 100 mum apart to exclude overlapping islets. Immunohistochemistry was performed using anti-insulin antibody and counterstaining with hematoxylin. Using Adobe Photoshop, the area of insulin-positive islets and total pancreatic tissue for every section was measured. beta-Cell mass was calculated as a product of total pancreatic weight and beta-cell area.
###end p 33
###begin title 34
RESULTS
###end title 34
###begin title 35
###xml 69 73 <span type="species:ncbi:10090">mice</span>
VHL inactivation in adult beta-cells leads to glucose intolerance in mice.
###end title 35
###begin p 36
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 296 300 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 324 332 318 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre/loxP</italic>
###xml 374 378 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 380 384 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 384 393 378 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 384 393 378 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 476 479 470 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre</italic>
###xml 600 604 594 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 604 613 598 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP/loxP</italic>
###xml 604 613 598 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>loxP/loxP</italic></sup>
###xml 727 729 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 730 732 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 790 794 781 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 794 803 785 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loxP/loxP</italic>
###xml 794 803 785 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>loxP/loxP</italic></sup>
###xml 952 957 943 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1</italic>
###xml 969 978 960 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 978 980 969 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 978 980 969 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 983 985 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 997 1002 988 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1</italic>
###xml 1138 1147 1126 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 1147 1149 1135 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 1147 1149 1135 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 1386 1395 1374 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 1395 1397 1383 1385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 1395 1397 1383 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 1402 1406 1390 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1406 1415 1394 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 1406 1415 1394 1403 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 1452 1456 1440 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1536 1545 1524 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 1545 1547 1533 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 1545 1547 1533 1535 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 1548 1552 1536 1540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1552 1561 1540 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 1552 1561 1540 1549 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 1685 1689 1673 1677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 33 39 <span type="species:ncbi:10090">murine</span>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 614 618 <span type="species:ncbi:10090">mice</span>
###xml 804 808 <span type="species:ncbi:10090">mice</span>
###xml 840 845 <span type="species:ncbi:10090">mouse</span>
###xml 1161 1166 <span type="species:ncbi:10090">mouse</span>
###xml 1361 1376 <span type="species:ncbi:10090">transgenic mice</span>
Homozygous deletion of Vhlh (the murine homolog of VHL) results in embryonic lethality due to defects in placental vasculogenesis, thus precluding the analysis of adult tissues in VHL-deficient mice (11). To investigate the role of VHL in adult beta-cell function, we specifically eliminated the Vhlh gene in beta-cells via Cre/loxP recombination. The conditional allele of Vhlh (VhlhLoxP/LoxP) provides the capability to knockout the VHL protein in a tissue-specific manner. Cre-mediated excision of the floxed allele deletes the promoter and the first exon of the gene, resulting in a null allele. VhlhloxP/loxP mice have been used previously to successfully analyze the role of VHL in other organs such as liver and kidney (13,14). To specifically inactivate VHL function in beta-cells, VhlhloxP/loxP mice were crossed with a transgenic mouse line that expresses the Cre recombinase under the control of the pancreatic and duodenal homeobox gene 1 (Pdx-1) promoter (Pdx-1-CreER) (19). Although Pdx-1 is broadly expressed during development, it becomes restricted to insulin producing beta-cells in animals around 4-6 weeks of age. The Pdx-1-CreER transgenic mouse line carries an altered form of the Cre recombinase that is fused to the estrogen receptor, rendering the protein inactive in the cytoplasm in the absence of the tamoxifen ligand. Double mutant transgenic mice carrying Pdx-1-CreER and VhlhLoxP/LoxP allow for appropriate expression of Vhlh in the absence of tamoxifen treatment, thereby ensuring normal development. In Pdx-1-CreER;VhlhLoxP/LoxP adults, exposure to tamoxifen leads to nuclear translocation of the Cre recombinase, allowing irreversible inactivation of Vhlh at a desired time.
###end p 36
###begin p 37
###xml 16 25 16 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 25 27 25 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 25 27 25 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 32 41 32 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 32 41 32 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 324 333 324 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 333 335 333 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 333 335 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 340 349 340 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 340 349 340 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 559 562 556 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre</italic>
###xml 595 604 592 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 604 606 601 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 604 606 601 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 607 611 604 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 611 620 608 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 611 620 608 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 622 631 619 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 631 633 628 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 631 633 628 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 634 638 631 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 640 644 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP</italic>
###xml 638 644 635 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>LoxP</italic></sup>
###xml 650 654 647 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 654 663 651 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 654 663 651 660 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 690 691 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 684 691 681 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 736 745 733 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 745 747 742 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 745 747 742 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 748 752 745 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 752 761 749 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 752 761 749 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 832 833 829 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 826 833 823 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 854 863 851 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 863 865 860 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 863 865 860 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 866 870 863 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 870 879 867 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 870 879 867 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
###xml 887 891 <span type="species:ncbi:10090">mice</span>
###xml 1165 1170 <span type="species:ncbi:10090">mouse</span>
As anticipated, Pdx-1-CreER;VhlhLoxP/LoxP mutant mice were born in the expected Mendelian ratio and reached adulthood without any sign of compromised health. Administering tamoxifen to 8- to 10-week-old mice induced Cre expression in adult islets. Blood glucose concentration was monitored weekly after tamoxifen treatment. Pdx-1-CreER;VhlhLoxP/LoxP mice treated with tamoxifen displayed normal fed and fasting blood glucose levels. To more vigorously test beta-cell function, the response of these mice to a glucose challenge was assessed. In the absence of Cre expression, all mice (including Pdx-1-CreER;VhlhLoxP/LoxP, Pdx-1-CreER;Vhlh+/LoxP, and VhlhLoxP/LoxP) are normoglycemic (Fig. 1A). However, the ability of tamoxifen-treated Pdx-1-CreER;VhlhLoxP/LoxP mutant mice to recover after the glucose challenge is impaired (Fig. 1B). Tamoxifen-treated Pdx-1-CreER;VhlhLoxP/LoxP mutant mice do not reach normoglycemia until 3 h after the glucose challenge (data not shown). Interestingly, the glucose-intolerant phenotype develops 6-8 weeks after the start of the tamoxifen regimen. Thus, VHL function in the adult beta-cell affects glucose homeostasis within the mouse.
###end p 37
###begin p 38
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 175 176 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 169 176 169 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 178 187 178 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top panel</italic>
###xml 223 224 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 217 224 217 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 226 238 226 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom panel</italic>
###xml 545 554 545 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 554 556 554 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 554 556 554 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 557 564 557 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rosa26R</italic>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 565 580 <span type="species:ncbi:10090">transgenic mice</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
Successful excision of the Vhlh floxed allele was demonstrated by PCR on genomic DNA isolated from islets. Distinct sets of primers allow for detection of the genotype (Fig. 1C, top panel) and the extent of excision (Fig. 1C, bottom panel) in islets. Both mice were injected with tamoxifen and display a robust signal for amplification of the excised allele. To correlate the severity of the phenotypes observed with the efficiency of Cre-mediated recombination of the floxed alleles, we also performed an expression analysis of Cre activity in Pdx-1-CreER;Rosa26R transgenic mice. Histological analysis of pancreatic tissue from mice that underwent tamoxifen treatment reveals approximately80-90% excision (supplementary Fig. 1, found in an online appendix at ; data not shown).
###end p 38
###begin p 39
###xml 79 83 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 173 176 167 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre</italic>
###xml 216 223 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ins-Cre</italic>
###xml 226 228 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 231 243 225 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ins-Cre;Vhlh</italic>
###xml 243 252 237 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 243 252 237 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 478 479 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 472 479 463 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 551 563 539 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ins-Cre;Vhlh</italic>
###xml 563 572 551 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 563 572 551 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 623 632 608 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 632 634 617 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 632 634 617 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 635 639 620 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 639 648 624 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 639 648 624 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 151 156 <span type="species:ncbi:10090">mouse</span>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
To further confirm the role of VHL in beta-cell function, specific deletion of Vhlh in beta-cells during embryogenesis was achieved using a transgenic mouse line expressing Cre under control of the insulin promoter (Ins-Cre) (20). Ins-Cre;VhlhLoxP/LoxP mice develop to adulthood, with no overt defects. However, upon glucose challenge, mice with no functional VHL in beta-cells are unable to normalize their blood glucose levels, revealing a glucose-intolerant phenotype (Fig. 1D). Thus, inactivation of VHL in beta-cells either early in development (Ins-Cre;VhlhLoxP/LoxP mice) or after beta-cells have acquired maturity (Pdx-1-CreER;VhlhLoxP/LoxP) points to a role for VHL in beta-cell function.
###end p 39
###begin title 40
###xml 35 44 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 44 46 44 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 44 46 44 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 51 60 51 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 51 60 51 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Increased vasculature in islets of Pdx-1-CreER;VhlhLoxP/LoxP mice.
###end title 40
###begin p 41
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 196 205 193 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 205 207 202 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 205 207 202 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 208 212 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 212 221 209 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 212 221 209 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 301 310 298 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 310 312 307 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 310 312 307 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 313 317 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 317 326 314 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 317 326 314 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 417 418 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 423 424 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 411 424 408 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 604 608 597 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vegf</italic>
###xml 611 613 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 668 677 661 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 677 679 670 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 677 679 670 672 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 680 684 673 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 684 693 677 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 684 693 677 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 800 803 793 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C&#8211;H</italic>
###xml 794 803 787 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C&#8211;H</italic></xref>
###xml 822 826 815 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vegf</italic>
###xml 898 899 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 892 899 885 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>I</italic></xref>
###xml 1065 1074 1058 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 1074 1076 1067 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 1074 1076 1067 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 1077 1081 1070 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1081 1090 1074 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 1081 1090 1074 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 1110 1113 1103 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;D</italic>
###xml 1104 1113 1097 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A&#8211;D</italic></xref>
###xml 1299 1300 1292 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1305 1306 1298 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1293 1306 1286 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic> and <italic>D</italic></xref>
###xml 1388 1390 1381 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1414 1417 1407 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E&#8211;H</italic>
###xml 1408 1417 1401 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>E&#8211;H</italic></xref>
###xml 1453 1465 1443 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ins-Cre;Vhlh</italic>
###xml 1465 1474 1455 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 1465 1474 1455 1464 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
###xml 1098 1102 <span type="species:ncbi:10090">mice</span>
The defect in glucose homeostasis that results from the inactivation of Vhlh in beta-cells raises the question of whether islet formation and/or architecture could be altered in tamoxifen-treated Pdx-1-CreER;VhlhLoxP/LoxP mutant mice. Histological analysis of pancreatic tissue from tamoxifen-treated Pdx-1-CreER;VhlhLoxP/LoxP mutant mice does not reveal any morphological changes compared with control tissue (Fig. 2A and B). A hallmark of the VHL syndrome is increased vasculature within tumors, which correlates with a HIF-1alpha-mediated increase in expression of vascular endothelial growth factor (Vegf) (10). In agreement with this, islets in tamoxifen-treated Pdx-1-CreER;VhlhLoxP/LoxP mutant mice display a dramatic increase in blood vessels, as marked by PECAM-1/CD31 immunostaining (Fig. 2C-H). The increase in Vegf expression was confirmed by quantitative real-time PCR analysis (Fig. 2I). Immunostaining analysis for the hormones insulin, glucagon, and somatostatin reveal that the overall architecture of the islets is maintained in tamoxifen-treated Pdx-1-CreER;VhlhLoxP/LoxP mutant mice (Fig. 3A-D). The increased vasculature may explain the apparent perturbation of islet morphology in tissue lacking functional VHL, observed as gaps or holes when stained for hormones alone (Fig. 3B and D). In addition, expression of mature endocrine markers including Nkx6.1 and Pax6 (26) appears normal (Fig. 3E-H). beta-Cell mass quantification in Ins-Cre;VhlhLoxP/LoxP pancreas revealed no difference between the control and mutant groups (supplementary Fig. 3). Thus, VHL is not essential for islet formation and beta-cell differentiation.
###end p 41
###begin title 42
Impaired insulin secretion in beta-cells lacking VHL.
###end title 42
###begin p 43
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 229 236 229 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 297 306 297 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 306 308 306 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 306 308 306 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 547 556 547 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 556 558 556 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 556 558 556 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 559 563 559 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 563 572 563 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 563 572 563 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 699 703 699 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 825 834 825 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 834 836 834 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 834 836 834 836 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 837 840 837 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 840 849 840 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 840 849 840 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 930 931 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 936 937 936 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 924 937 924 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic> and <italic>C</italic></xref>
###xml 1056 1057 1053 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1062 1063 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1050 1063 1047 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic> and <italic>C</italic></xref>
###xml 1264 1265 1258 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1258 1265 1252 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 714 718 <span type="species:ncbi:10090">mice</span>
###xml 851 855 <span type="species:ncbi:10090">mice</span>
###xml 903 907 <span type="species:ncbi:10090">mice</span>
To determine whether the lack of recovery to normoglycemia after glucose challenge in Vhlh mutant mice is due to defective insulin secretion, blood serum from resting and challenged mice was collected for insulin quantification (Fig. 4A and supplementary Fig. 2). Control mice (either without the Pdx-1-CreER transgene or harboring the transgene but not injected with tamoxifen) display elevated insulin levels in the serum 30 min after glucose challenge. Strikingly, a significant decrease in circulating insulin is observed in tamoxifen-treated Pdx-1-CreER;VhlhLoxP/LoxP mutant mice after a 30-min glucose challenge. To determine the basis of the defect in glucose-stimulated insulin secretion in Vhlh-deficient mice, insulin secretion assays were carried out on islets isolated from control and mutant (tamoxifen-injected Pdx-1-CreER;VHLLoxP/LoxP) mice. Resting insulin levels for control and mutant mice are comparable (Fig. 4B and C). However, the insulin secretory response to glucose is markedly reduced in islets with beta-cells lacking VHL (Fig. 4B and C). To determine whether beta-cells were primed for secretion, control and mutant islets were incubated with a nonglucose secretagogue, KCl. In the presence of KCl, mutant islets secrete insulin (Fig. 4C), indicating that beta-cells lacking VHL possess a functional secretion machinery. Summarily, these results show that loss of VHL in beta-cells leads to a severe inability to secrete insulin in response to increased glucose concentration.
###end p 43
###begin p 44
###xml 274 280 274 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 421 422 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 415 422 415 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 540 541 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 534 541 534 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 692 696 692 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 528 532 <span type="species:ncbi:10090">mice</span>
###xml 707 711 <span type="species:ncbi:10090">mice</span>
Two likely explanations for the decrease in glucose-stimulated insulin secretion could be envisioned-either insulin production is reduced, or insulin secretion is affected. By immunohistochemistry, insulin levels in the mutant islets do not appear significantly diminished (Fig. 3). By quantitative PCR analysis, there is a mild reduction in insulin transcript levels, although it is not statistically significant (Fig. 4D). This is reflected in the minor reduction of total insulin protein observed in islets of Vhlh-deficient mice (Fig. 4E). It appears unlikely that the modest decrease in insulin level could account for the complete lack of secretion upon glucose stimulation observed in Vhlh-deficient mice. Thus, we decided to identify additional changes in beta-cells that might contribute to the defect in insulin secretion.
###end p 44
###begin title 45
Modulation of glycolytic metabolism in the absence of VHL.
###end title 45
###begin p 46
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 618 620 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 621 623 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 734 738 731 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 919 920 916 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 913 920 910 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 980 985 977 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gapdh</italic>
###xml 1012 1015 1009 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pgk</italic>
###xml 1039 1042 1036 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfk</italic>
###xml 1074 1077 1071 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gpi</italic>
###xml 1092 1097 1089 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AldoA</italic>
###xml 1124 1128 1121 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pgm2</italic>
###xml 1137 1138 1134 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1131 1138 1128 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 1157 1161 1154 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1248 1250 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1251 1253 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 1315 1321 1312 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut-1</italic>
###xml 1336 1340 1333 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1365 1366 1362 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1359 1366 1356 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 1491 1495 1485 1489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1520 1521 1514 1515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1514 1521 1508 1515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 1601 1602 1595 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1595 1602 1589 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
In human cancers and mouse models, a loss of VHL is accompanied by an increase in the expression of several genes related to glucose metabolism (1,3). These genes include glucose transporters and enzymes of the glycolytic pathway. This coordinated increase in gene expression results in a switch from oxidative phosphorylation to glycolytic metabolism within cells. Such a dramatic shift in glucose metabolism presumably allows cells to maintain energy homeostasis and reduce the buildup of reactive oxygen species (1). Perturbation of glucose metabolism in beta-cells has been linked to defects in insulin secretion (27-29). Therefore, we decided to test whether the expression of genes involved in glucose metabolism is affected in Vhlh-deficient mice. Gene expression of several enzymes involved in glucose metabolism, as assessed by quantitative PCR analysis is significantly increased in islets lacking VHL (Fig. 5A). These include glyceraldehyde-3-phosphaste-dehydrogenase (Gapdh), phosphoglyceratekinase (Pgk), phosphofructokinase (Pfk), glucose phosphate isomerase (Gpi), aldolase A (AldoA), and phosphoglucomutase (Pgm2) (Fig. 5A). Inactivation of Vhlh has also been shown to affect the expression of glucose transporters GLUT1 and GLUT2 (14,16). In agreement with these reports, we observe an increase in Glut-1 expression in Vhlh-deficient islets (Fig. 5A). Interestingly, GLUT2, the transporter that enables facilitative transport of glucose into beta-cells, is downregulated in Vhlh-deficient islets (Fig. 5A). Immunohistochemical analysis confirms the dramatic reduction of GLUT2 (Fig. 5B). Thus, loss of VHL in beta-cells appears to disturb the cellular machinery for glucose sensing and metabolism.
###end p 46
###begin p 47
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LDHa</italic>
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 116 123 116 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK</italic>
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 165 172 165 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LDHa</italic>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 829 833 829 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCT4</italic>
###xml 841 842 841 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 835 842 835 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 995 999 995 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1178 1179 1175 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1172 1179 1169 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 1199 1203 1196 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LDHa</italic>
###xml 1205 1208 1202 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK</italic>
###xml 1214 1218 1211 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCT4</italic>
Gene expression assessment by quantitative PCR also revealed a significant increase in lactate dehydrogenase (LDHa, Fig. 5C) and pyruvate dehydrogenase kinase (PDK, Fig. 5C). LDHa catalyzes the conversion of pyruvate to lactate and is maintained at low levels in islets during homeostasis (30), presumably to ensure maximal amounts of pyruvate being shunted toward oxidative phosphorylation. PDK is an inhibitor of pyruvate dehydrogenase, which normally catalyzes the conversion of pyruvate to acetyl CoA for entry into the tricarboxylic acid cycle. Upregulation of PDK leads to a decrease in pyruvate dehydrogenase activity, consequently decreasing oxidation of pyruvate in the mitochondria and increasing the pyruvate-to-lactate conversion in the cytosol. Indeed, VHL mutant islets show a drastic increase in the expression of MCT4 (Fig. 5C), a monocarboxylate transporter that mediates efflux of lactate from glycolytically active cells (31). Quantitative PCR analysis indicates that loss of Vhlh in beta-cells results in increased glycolytic metabolism. In agreement with these results, we detected increased lactate in the growth medium upon culturing mutant islets (Fig. 5D). Thus, given that LDHa, PDK, and MCT4 are all downstream targets of HIFalpha proteins, the concerted increased activity of these genes points to a modification of intracellular respiration that may lead to a block in glucose-stimulated insulin secretion.
###end p 47
###begin title 48
DISCUSSION
###end title 48
###begin p 49
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 234 238 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 256 264 250 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cre-loxP</italic>
###xml 293 297 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
The von Hippel-Lindau tumor suppressor gene product (VHL) is an essential component of the cellular response to hypoxia (8,9). To gain insight into the role of VHL in beta-cell formation and function, we have specifically inactivated Vhlh in beta-cells by Cre-loxP mutagenesis. Elimination of Vhlh in embryonic and mature beta-cells reveals that VHL is dispensable for beta-cell formation and differentiation. However, loss of VHL has profound effects on beta-cell function, demonstrating a novel role for VHL in maintaining glucose homeostasis.
###end p 49
###begin p 50
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 323 327 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 539 543 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 811 815 793 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 989 993 971 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1221 1225 1203 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
###xml 1472 1476 <span type="species:ncbi:10090">mice</span>
Mice lacking Vhlh in adult beta-cells develop severe glucose intolerance. The phenotype onset occurs with a slight delay that is not completely understood, and future work could address whether slow turnover of the existing stores of VHL might provide an explanation. Our results show that total insulin protein content in Vhlh-deficient islets is not significantly reduced. These results point to a specific defect in insulin secretion as the underlying cause of the glucose intolerance phenotype. Basal unstimulated insulin secretion in Vhlh-deficient mice parallels that of control littermates. In fact, when challenged with high glucose, mice lacking VHL in beta-cells normalize blood glucose approximately3 h after the control group, an effect that might be explained by basal insulin secretion. In vitro, Vhlh-deficient islets fail to secrete elevated levels of insulin when incubated with high glucose, uncovering a role for VHL in regulating the metabolic response. The ability of Vhlh-deficient islets to secrete insulin in the presence of KCl indicates the presence of a competent secretory system, placing the defect further upstream. As absolute levels of insulin secreted in the presence of KCl are lower in Vhlh-deficient islets, a defect in the exocytotic machinery cannot be ruled out. It is, however, important to note that the relative increase in insulin secretion in the presence of KCl compared with basal levels is similar between control and mutant mice.
###end p 50
###begin p 51
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 327 331 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vegf</italic>
###xml 336 341 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut1</italic>
###xml 636 638 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 639 641 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 976 977 965 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 1070 1072 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 1177 1179 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 1180 1182 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 1183 1185 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 1305 1307 1294 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 1308 1310 1297 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 1297 1303 <span type="species:ncbi:9606">humans</span>
These results raise the question of how the loss of VHL affects insulin secretion. Previous work has demonstrated that hypoxia impairs insulin secretion (32-34). VHL inactivation, via HIF-1alpha stabilization, mimics certain aspects of the cellular response to hypoxia, and canonical target genes of the HIF complex, including Vegf and Glut1, are significantly upregulated in VHL-depleted islets. Similar to our in vivo studies, in vitro experiments performed on isolated islets have shown that hypoxic conditions lead to an almost complete block in glucose-stimulated insulin secretion, while basal secretion is only slightly reduced (32,34). While the mechanism by which hypoxia impairs insulin secretion is not completely understood, it is generally believed to involve the depletion of energy stores in beta-cells. During hypoxia, and through HIF-1alpha function, a switch from oxidative phosphorylation to aerobic glycolysis occurs, resulting in impaired ATP production (1). The ATP-to-ADP ratio has been proposed as a major regulator of insulin secretion (rev. in 29). Defects in ATP production have been linked to impairment of insulin secretion in response to glucose (27,33,35). Furthermore, mitochondrial mutations that result in decreased ATP production have been linked to diabetes in humans (36-38).
###end p 51
###begin p 52
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 328 333 328 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gapdh</italic>
###xml 335 338 335 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfk</italic>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pgm2</italic>
###xml 458 462 458 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 560 564 560 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LDHa</italic>
###xml 600 603 600 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK</italic>
###xml 629 633 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCT4</italic>
###xml 705 709 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LDHa</italic>
###xml 807 809 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 929 933 923 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1168 1174 1155 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut-2</italic>
###xml 1190 1194 1177 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1237 1243 1224 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut-2</italic>
###xml 1300 1302 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 1303 1305 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 1328 1335 1315 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut-2&#8211;</italic>
###xml 1405 1407 1392 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 1497 1501 1481 1485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1562 1568 1546 1552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut-2</italic>
###xml 1587 1588 1571 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1581 1588 1565 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 1632 1633 1616 1617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1633 1634 1617 1618 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 1709 1715 1693 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut-2</italic>
###xml 1856 1862 1840 1846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut-2</italic>
###xml 1866 1870 1850 1854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1870 1873 1854 1857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
###xml 1345 1349 <span type="species:ncbi:10090">mice</span>
###xml 1512 1516 <span type="species:ncbi:10090">mice</span>
Both hypoxia and loss of VHL induce the expression of genes related to the glycolytic pathway that could lead to decreased ATP production. We observe upregulation of several genes that indicate a switch from oxidative phosphorylation to glycolytic metabolism in Vhlh-deficient islets. Among other genes, increased expression of Gapdh, Pfk, and Pgm2 is observed. Further evidence of a shift away from oxidative phosphorylation as the primary energy source in Vhlh-deficient islets was the dramatic increase in expression of genes involved in lactate formation (LDHa), regulation of lactate formation (PDK), and lactate secretion (MCT4) as well as increased lactate in the culture medium. Overexpression of LDHa has been shown to attenuate glucose-induced insulin secretion in the mature beta-cell line MIN6 (39). Together, these observations point to defects in glucose metabolism as a possible cause for beta-cell dysfunction in Vhlh-deficient mice. The VHL-HIF-1alpha axis controls the expression of a large number of genes. We cannot formally exclude that alterations in other genes might influence beta-cell function. Indeed, expression of the glucose transporter, Glut-2, is reduced in Vhlh-deficient islets. Decreased expression of Glut-2 has been reported in several animal models of diabetes (40-42). In vitro, islets of Glut-2-deficient mice display impaired glucose-stimulated insulin secretion (43). Therefore, defective islet glucose uptake could play a role in beta-cell impairment in Vhlh-deficient mice. However, a reduction but not elimination of Glut-2 expression (Fig. 5B) might not hinder glucose uptake below the Km threshold for glucokinase. Under these circumstances, the contribution of Glut-2 in the development of the observed phenotype might be minor. Further analysis will elucidate the precise consequence of decreased levels of Glut-2 in Vhlh-/- islets.
###end p 52
###begin p 53
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 519 521 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 208 212 <span type="species:ncbi:10116">rats</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
###xml 607 622 <span type="species:ncbi:10090">transgenic mice</span>
###xml 743 751 <span type="species:ncbi:9606">patients</span>
Additional evidence points to defective signaling due to hypoxia as a contributor to diabetes. Upregulation of hypoxia-related genes has been observed in pre-diabetic and diabetic Zucker diabetic fatty (ZDF) rats (44). Recent studies suggest that inhibition of the hypoxic response also affects beta-cell function. A dramatic decrease in HIF-1beta (ARNT), the partner of HIF-1alpha, was reported in islets obtained from type 2 diabetic patients, indicating an involvement of the hypoxia genes in beta-cell dysfunction (45). Furthermore, the authors showed that a beta-cell-specific knockout of HIF-1beta in transgenic mice leads to abnormal glucose tolerance, and the genetic changes in islets overlap with those found in islets from diabetic patients. In agreement with our results, some of the genes affected in beta-cells lacking HIF-1beta are involved in glucose sensing and metabolism. It is possible that dysregulation of the glycolytic pathway (either by upregulation or downregulation) impairs beta-cell function.
###end p 53
###begin p 54
###xml 211 215 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vegf</italic>
###xml 356 360 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vegf</italic>
###xml 454 456 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 457 459 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 318 323 <span type="species:ncbi:10090">mouse</span>
Although our results strongly suggest that cell autonomous changes in beta-cells impair glucose regulation, we cannot formally exclude the scenario that the aberrations in islet architecture caused by increased Vegf expression might influence beta-cell function. However, previously reported studies in other existing mouse models that ectopically express Vegf either in beta-cells or in the pancreas have failed to report glucose-intolerant phenotypes (46,47). Nonetheless, it cannot be excluded that inappropriately increased vascularization might impede insulin secretion, possibly through incorrectly established contacts between the beta-cells and the endothelium. Future work will need to address this issue.
###end p 54
###begin p 55
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 384 388 384 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 475 479 475 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 704 708 698 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 834 836 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 58 64 <span type="species:ncbi:9606">humans</span>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
VHL is a tumor suppressor gene. Germline VHL mutations in humans predispose to certain types of tumors, affecting several organs, including the kidney and pancreas (10). Although the most frequent pancreatic manifestation of VHL disease is serous cysts, a small percentage of VHL patients develop nonfunctional islet cell tumors (17,18). We have not observed islet tumor formation in Vhlh-deficient mice. However, it is important to note that in our studies, inactivation of Vhlh has been restricted to beta-cells. The cell of origin of islet tumors in VHL patients is not known. Therefore, islet tumor formation might require loss of VHL in other non-beta-cells. Alternatively, islet tumor formation in Vhlh-deficient beta-cells might involve a second event, as has been described for other VHL-related tumors such as in the kidney (48).
###end p 55
###begin p 56
###xml 137 141 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 598 600 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
In summary, we have shown that loss of VHL in beta-cells leads to defects in glucose homeostasis. We believe that the beta-cell-specific Vhlh-deficient mice might be a useful tool as a "genetic hypoxia" model, to unravel the possible link between hypoxia signaling and impairment of beta-cell function. This is particularly important, since the beta-cell response to hypoxia could also be relevant for therapeutic approaches to diabetes. Islet transplantation studies have noted a dramatic increase in HIF-1 levels soon after transplantation that causes apoptosis and a block in insulin secretion (49). Thus, preventing hypoxic conditions might not only affect transplant survival but also prevent changes in insulin secretion.
###end p 56
###begin title 57
Supplementary Material
###end title 57
###begin title 58
Online-Only Appendix
###end title 58
###begin p 59
S.P. was supported by a postdoctoral fellowship from the Juvenile Diabetes Research Foundation and a Klein Family Foundation Fellowship. D.C. was supported by a postdoctoral fellowship from the California Institute of Regenerative Medicine (CIRM). Work in M.H.'s laboratory was supported by grants from the National Institutes of Health (DK60533) and a Scholar Award from the Juvenile Diabetes Research Foundation. Image acquisition was supported by the UCSF Diabetes and Endocrinology Research Center microscopy core (P30 DK63720).
###end p 59
###begin p 60
No potential conflicts of interest relevant to this article were reported.
###end p 60
###begin p 61
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
We would like to thank Drs. Doug Melton and Pedro Herrera for providing us with mouse lines used in this work and Dr. Mike German for providing antibody reagents.
###end p 61
###begin title 62
REFERENCES
###end title 62
###begin p 63
###xml 61 62 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 114 123 111 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 123 125 120 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 123 125 120 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 126 129 123 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 131 135 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP</italic>
###xml 129 135 126 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>LoxP</italic></sup>
###xml 137 138 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 148 157 145 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 157 159 154 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 157 159 154 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 160 163 157 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 163 172 160 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 163 172 160 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 184 185 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 245 246 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 284 293 281 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 293 295 290 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 293 295 290 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 296 299 293 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 299 308 296 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 299 308 296 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 492 493 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 506 507 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 512 514 509 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 516 517 513 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 597 600 594 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 600 609 597 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 600 609 597 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 697 706 694 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 706 708 703 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 706 708 703 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 710 719 707 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Top panel</italic>
###xml 922 933 919 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 936 937 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 945 952 942 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ins-Cre</italic>
###xml 953 956 950 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 956 965 953 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 956 965 953 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 1056 1063 1053 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ins-Cre</italic>
###xml 1064 1067 1061 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 1067 1076 1064 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 1067 1076 1064 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 1094 1095 1091 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1182 1183 1179 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1277 1278 1274 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1291 1292 1288 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1297 1299 1294 1296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 401 405 <span type="species:ncbi:10090">mice</span>
###xml 836 840 <span type="species:ncbi:10090">mice</span>
###xml 966 970 <span type="species:ncbi:10090">mice</span>
###xml 1077 1081 <span type="species:ncbi:10090">mice</span>
VHL inactivation in beta-cells leads to glucose intolerance. A: In the absence of tamoxifen, control (black line, Pdx-1-CreER;VHL+/LoxP, n = 6) and Pdx-1-CreER;VHLLoxP/LoxP(gray line, n = 3) mice normalize blood glucose 120 min after challenge. B: At 120 min after glucose challenge, Pdx-1-CreER;VHLLoxP/LoxP mice (gray line) injected with tamoxifen have elevated glucose levels compared with control mice (black line). Eleven animals were analyzed per group from eight independent cohorts. *P < 0.001, ***P < 10-8. C: PCR on genomic DNA from transgenic islets heterozygous and homozygous for the VHLLoxP/LoxP allele demonstrates the extent of Cre-mediated excision. Both samples are positive for Pdx-1-CreER. Top panel: The genotype of the islets. The wild-type allele in the heterozygous sample (*) runs below the floxed allele. Both mice were injected with tamoxifen and display a robust signal for the excised allele (lower panel). D: Adult Ins-Cre;VHLLoxP/LoxP mice are glucose intolerant. Two hours after the glucose challenge, the 8- to 10-week-old Ins-Cre;VHLLoxP/LoxP mice (gray line, n = 14) have elevated glucose levels compared with the control littermates (black line, n = 11). Control and mutant animals from nine independent cohorts were used for the analysis. *P < 0.001, ***P < 10-8. Error bars represent SD in all cases.
###end p 63
###begin p 64
###xml 109 110 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 116 120 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 120 123 117 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 125 126 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 249 250 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 255 256 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 271 272 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 277 278 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 332 341 328 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 341 343 337 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 341 343 337 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 344 347 340 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 347 356 343 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 347 356 343 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 363 364 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 366 367 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 373 374 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 439 440 435 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 442 443 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 449 450 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 485 486 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 491 492 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 507 508 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 576 585 571 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 585 587 580 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 585 587 580 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 589 592 584 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 592 601 587 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 592 601 587 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 628 632 623 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vegf</italic>
###xml 670 671 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 679 680 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
Islet morphology upon VHL inactivation in adult beta-cells. Hematoxylin and eosin (H&E) analysis of control (A) and Vhlh-/- (B) tissue shows aberrant islet architecture due to increased blood vessel density. Bar, 20 mum. Immunostaining for insulin (C and D) and PECAM-1 (E and F) reveals that islet morphology in tamoxifen-injected Pdx-1-CreER;VHLLoxP/LoxP mice (D, F, and H) displays increased vasculature compared with the control mice (C, E, and G). The overlay images are shown in G and H. Bar, 50 mum. I: Real-time PCR analysis on islets isolated from tamoxifen-injected Pdx-1-CreER; VHLLoxP/LoxP mice shows an increase in Vegf expression (error bars represent SD, n = 5. **P < 0.005). (Please see  for a high-quality digital representation of this image.)
###end p 64
###begin p 65
###xml 165 168 159 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;H</italic>
###xml 197 198 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 203 204 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 241 242 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 247 248 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 282 283 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 288 289 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 310 311 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 316 317 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 358 359 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 364 365 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 382 383 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 388 389 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
VHL is not essential for islet formation and beta-cell differentiation. Adult mice lacking VHL in beta-cells maintain islet architecture. Insulin-expressing (green, A-H), glucagon-expressing (red, A and B), and somatostatin-expressing (red, C and D) cells are found in the control (A and C) and mutant tissue (B and D). Mature beta-cell markers Nkx6.1 (red, E and F) and Pax6 (red, G and H) continue to be expressed in the absence of VHL. Bar, 50 mum. (Please see  for a high-quality digital representation of this image.)
###end p 65
###begin p 66
###xml 76 77 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 198 207 195 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 207 209 204 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 207 209 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 210 213 207 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 213 222 210 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 213 222 210 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 355 356 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 365 366 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 639 640 636 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 649 650 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 661 662 658 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 794 795 791 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 803 804 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 828 831 825 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;C</italic>
###xml 968 969 965 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 976 977 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1142 1146 1139 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ins1</italic>
###xml 1148 1149 1145 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1157 1161 1154 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ins2</italic>
###xml 1163 1164 1160 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1174 1175 1171 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1181 1182 1178 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1295 1296 1292 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1304 1305 1301 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
VHL inactivation in adult beta-cells leads to a block in insulin secretion. A: Serum insulin measurements 30 min after glucose challenge show an absence of circulating insulin in tamoxifen-injected Pdx-1-CreER;VHLLoxP/LoxP mutant mice compared with control littermates. Four animals per group were included in the analysis from four independent cohorts. *P < 0.05. B: In vitro insulin secretion assay carried out on isolated islets demonstrates a block in insulin secretion upon incubation with high (16.67 mmol/l) glucose in the absence of VHL. Basal secretion (low glucose, 1.67 mmol/l) was comparable between control and mutant islets. n = 3. ***P < 0.0005. C: Incubation of mutant islets with 40 mmol/l KCl in the presence of high (16.67 mmol/l) glucose induces insulin secretion in vitro. n = 3. **P < 0.001. Significance (A-C) was determined between the amount of insulin secreted under high glucose conditions from control and mutant islets using the Student's t test. D: Real-time PCR of insulin transcript levels shows a moderate decrease of insulin in mutant animals (gray bars) when compared with the control animals (black bars) (Ins1, P > 0.1; Ins2, P > 0.01). n = 3. E: Total insulin levels were calculated in islets isolated from control (black bar) or mutant animals (gray bar). P > 0.1, n = 3. Error bars represent SD in all cases.
###end p 66
###begin p 67
###xml 71 72 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 402 408 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut-1</italic>
###xml 433 439 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut-2</italic>
###xml 495 499 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 499 502 499 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 705 706 705 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 810 819 810 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdx-1-Cre</italic>
###xml 819 821 819 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 819 821 819 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ER</italic></sup>
###xml 822 825 822 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
###xml 825 834 825 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LoxP/LoxP</italic>
###xml 825 834 825 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>LoxP/LoxP</italic></sup>
###xml 843 844 843 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 978 982 978 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ldha</italic>
###xml 1016 1019 1016 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK</italic>
###xml 1058 1062 1058 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCT4</italic>
###xml 1093 1097 1093 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vhlh</italic>
###xml 1097 1100 1097 1100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1142 1143 1142 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1408 1409 1405 1406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1420 1421 1417 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1433 1434 1430 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Glucose metabolism genes dysregulated in islets upon VHL inactivation. A: Quantitative PCR analysis of relative transcript levels of glycolytic enzymes reveals an upregulation of several members of the metabolic machinery in the absence of VHL. The housekeeping gene cyclophilin A was used to normalize gene expression. Changes in glucose transporters were also observed. The canonical HIF target gene Glut-1 is upregulated, whereas Glut-2 is downregulated. The change in expression of genes in Vhlh-/- islets was normalized to expression in control animals that was set to one (represented by the dotted line). Between three and five mutant and control animals were used for isolation of islets for RNA. B: Immunostaining for GLUT2 confirms significant downregulation of the transporter in tamoxifen-injected Pdx-1-CreER;VHLLoxP/LoxP islets. C: Increased expression of genes regulating the formation and export of lactate in islets. Transcript levels of lactate dehydrogenase (Ldha), pyruvate dehydrogenase kinase (PDK), and the monocarboxylate transporter MCT4 are dramatically increased in Vhlh-/- islets, as detected by quantitative PCR. D: beta-Cells lacking VHL secrete an increased amount of lactate into the surrounding medium (gray bar graph) compared with control islets (black bar graph). Islets isolated from three animals per group from three independent cohorts were included in the analysis. *P < 0.05, **P < 0.01, ***P < 0.005. Error bars represent SD in all cases. (Please see  for a high-quality digital representation of this image.)
###end p 67

